GLP-1 and GIP – How They Aid in Weight Loss

Medical weight loss has entered a new era with the introduction of incretin-based therapies. For patients at Scottsdale Weight Loss Center in Scottsdale, Phoenix, and Glendale, AZ, understanding the biological synergy of GLP-1 and GIP for weight loss is the first step toward achieving sustainable results. These medical tools do more than suppress appetite; they optimize the metabolic environment to support long-term success.

Understanding Incretin Hormones

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) are incretin hormones that play crucial roles in regulating blood sugar levels, particularly in response to food intake. Both hormones are released from the gut in response to ingested food, and they have several actions that contribute to glucose homeostasis.

GLP-1 is primarily produced in the distal small intestine and colon and enhances glucose-dependent insulin release from pancreatic β-cells. GIP is also produced in the small intestine, and one of its primary effects is to directly stimulate insulin secretion in pancreatic islets. Insulin is a hormone that helps cells take up glucose from the bloodstream, reducing blood sugar levels.

The Science of Satiety: How GLP-1 and GIP Change the Weight Loss Game

GLP-1 (Glucagon-Like Peptide-1):

• Stimulation of Insulin Release: GLP-1 enhances insulin secretion from pancreatic beta cells. Insulin is a hormone that helps cells take up glucose from the bloodstream, reducing blood sugar levels.
• Inhibition of Glucagon Release: GLP-1 also inhibits glucagon release, another pancreatic hormone. Glucagon raises blood sugar levels by promoting the release of glucose from the liver. Inhibiting glucagon can improve blood sugar control.
• Slowing Gastric Emptying: GLP-1 slows gastric emptying, leading to a feeling of fullness (satiety). This effect reduces nutrient absorption, prolonging the sense of fullness after meals.
• Central Nervous System Effects: GLP-1 receptors are also found in the central nervous system, particularly in the brain regions associated with appetite and food intake. Activating these receptors can reduce appetite and food intake.

GIP (Glucose-Dependent Insulinotropic Peptide):

• Insulin Release: GIP stimulates insulin release from the pancreas, which helps lower blood sugar levels by promoting glucose uptake by cells.
• Increased Glucagon Release: Unlike GLP-1, GIP increases the release of glucagon in a glucose-dependent manner. There is an enhanced release of glucagon from the pancreas at lower glycemia (blood sugar).
• Promotion of lipogenesis in adipose tissue: GIP has been associated with increased lipogenesis, the process of fat synthesis. This action suggests that GIP may play a role in adipose tissue fat storage.

The Dual-Action Advantage: Why GIP Makes a Difference

While GLP-1 has long been a benchmark in obesity medicine, adding GIP creates a “dual-agonist” effect. GIP influences fat synthesis and works with GLP-1 to signal the brain’s satiety centers more effectively. This combination often leads to more significant weight reduction than single-agonist medications alone.

The combined effects of increased insulin release, reduced glucagon secretion, slower gastric emptying, and appetite suppression contribute to weight loss in individuals taking GLP-1/GIP medications.

Zepbound, Wegovy, and Beyond: Which is Right for You?

Choosing between medications like Wegovy® (a GLP-1) and Zepbound® (a dual GLP-1/GIP agonist) requires a personalized approach. At Scottsdale Weight Loss Center, our medical weight loss doctors will evaluate your metabolic profile to determine which hormone profile fits your unique needs. You can compare these programs to find the one that aligns with your health goals.

Are you looking for Zepbound or Wegovy in Scottsdale? Don’t navigate your weight loss journey alone. Our medical team provides the clinical oversight you need to maximize results while minimizing side effects. Schedule a consultation now.

Why a Physician-Led Program is Essential for GLP-1 Success in Scottsdale

These medications are not “magic shots;” they are sophisticated medical tools that require expert titration. Our medical weight loss programs in Phoenix and Scottsdale ensure your dosing is personalized based on your weight-loss velocity and side-effect profile. This physician-led oversight is crucial for preventing plateaus and maintaining safety.

Dr. Ziltzer’s Take: Combining Medication with Metabolic Coaching

According to Dr. Robert Ziltzer, medication is only one piece of the puzzle. Our comprehensive programs combine these tools with nutritional coaching and behavioral support. To maintain accuracy in your care, we require a mandatory initial assessment before your physical and consultation. Once you begin your program, you can join our supportive Zoom classes via QR code found on your schedule.

Achieve Sustainable Results with Medical Weight Loss

If you are ready to move beyond traditional dieting, our physician-led team at Scottsdale Weight Loss Center is here to support your success. Talk to your clinician at Scottsdale Weight Loss Center and get started today!

About the Author

Robert Ziltzer, MD is a medical weight loss specialist at Scottsdale Weight Loss Center who provides patients with a medically supervised, evidence-based approach to achieving safe and lasting weight loss. He is board-certified in Obesity Medicine and is recognized among Arizona’s top physicians, having been consistently named a Top Doctor by Phoenix Magazine. Dr. Ziltzer takes a personalized, patient-centered approach to care, working closely with each individual to understand their health profile, lifestyle, and goals in order to develop a customized program that supports long-term success and improved overall wellness.

References

1. Grau-Bové C, González-Quilen C, Cantini G, Nardini P, Espina B, Bani D, Terra X, Blay M, Rodríguez-Gallego E, Luconi M, Ardévol A, Pinent M. GLP1 Exerts Paracrine Activity in the Intestinal Lumen of Human Colon. Int J Mol Sci. 2022 Mar 24;23(7):3523. doi: 10.3390/ijms23073523. PMID: 35408884; PMCID: PMC8998470.
2. Seino Y, Fukushima M, Yabe D. GIP, and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010 Apr 22;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x. PMID: 24843404; PMCID: PMC4020673.